Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Open access
Apperloo, Ellen M, Neuen, Brendon L, Fletcher, Robert A, Jongs, Niels, Anker, Stefan D, Bhatt, Deepak L, Butler, Javed, Cherney, David Z I, Herrington, William G, Inzucchi, Silvio E, Jardine, Meg J, Liu, Chih-Chin, Mahaffey, Kenneth W, McGuire, Darren K, McMurray, John J V, Neal, Bruce, Packer, Milton, Perkovic, Vlado, Sabatine, Marc S, Solomon, Scott D, Staplin, Natalie, Szarek, Michael, Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zannad, Faiez, Heerspink, Hiddo J L·2024·The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists. METHODS We conducted a collaborative meta-analysis of trials included in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, restricted to participants with diabetes. Treatment effects from individual trials were obtained from Cox regression models and pooled using inverse variance weighted meta-analysis. The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), and hospitalisation for heart failure or cardiovascular death. The main kidney outcomes assessed were chronic kidney disease progression (≥40% decline in estimated glomerular filtration rate [eGFR], kidney failure [eGFR <15 mL/min/1·73 m2, chronic dialysis, or kidney transplantation], or death due to kidney failure), and the rate of change in eGFR over time. Safety outcomes were also assessed. FINDINGS Across 12 randomised, double-blind, placebo-controlled trials, 3065 (4·2%) of 73 238 participants with diabetes were using GLP-1 receptor agonists at baseline. SGLT2 inhibitors reduced the risk of major adverse cardiovascular events in participants both receiving and not receiving GLP-1 receptor agonists (hazard ratio [HR] 0·81, 95% CI 0·63-1·03 vs 0·90, 0·86-0·94; p-heterogeneity=0·31). Effects on hospitalisation for heart failure or cardiovascular death (0·76, 0·57-1·01 vs 0·78, 0·74-0·82; p-heterogeneity=0·90) and chronic kidney disease progression (0·65, 0·46-0·94 vs 0·67, 0·62-0·72; p-heterogeneity=0·81) were also consistent regardless of GLP-1 receptor agonist use, as was the effect on the chronic rate of change in eGFR over time (heterogeneity=0·92). Fewer serious adverse events occurred with SGLT2 inhibitors compared with placebo, irrespective of GLP-1 receptor agonist use (relative risk 0·87, 95% CI 0·79-0·96 vs 0·91, 0·89-0·93; p-heterogeneity=0·41). INTERPRETATION The effects of SGLT2 inhibitors on cardiovascular and kidney outcomes are consistent regardless of the background use of GLP-1 receptor agonists. These findings suggest independent effects of these evidence-based therapies and support clinical practice guidelines recommending the use of these agents in combination to improve cardiovascular and kidney metabolic outcomes. FUNDING National Health and Medical Research Council of Australia and the Ramaciotti Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(24)00155-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 14

  1. ElSayed, 2024, Cardiovascular disease and risk management: standards of care in diabetes-2024, Diabetes Care, 47, S179
  2. Levin, 2024, Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns, Kidney Int, 105, 684, 10.1016/j.kint.2023.10.016 · DOI · Paper page
  3. Patel, 2024, Sodium glucose co-transporter 2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis, Circulation, 149, 1789, 10.1161/CIRCULATIONAHA.124.069568 · DOI · Paper page
  4. Mantsiou, 2020, Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis, Diabetes Obes Metab, 22, 1857, 10.1111/dom.14108 · DOI · Paper page
  5. Vernstrøm, 2024, Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial, Diabetes Obes Metab, 26, 1624, 10.1111/dom.15464 · DOI · Paper page
  6. van Ruiten, 2021, Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial, Diabetes Obes Metab, 23, 1851, 10.1111/dom.14410 · DOI · Paper page
  7. 2024, Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the Empa-kidney trial, Lancet Diabetes Endocrinol, 12, 39, 10.1016/S2213-8587(23)00321-2 · DOI
  8. Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
  9. Packer, 2022, Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis, Circulation, 146, 1383, 10.1161/CIRCULATIONAHA.122.061732 · DOI · Paper page
  10. Inker, 2023, A meta-analysis of GFR slope as a surrogate endpoint for kidney failure, Nat Med, 29, 1867, 10.1038/s41591-023-02418-0 · DOI · Paper page
  11. Neuen, 2023, Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data, Lancet Reg Health West Pac, 43
  12. Lamprea-Montealegre, 2022, Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease, Diabetes Care, 45, 2900, 10.2337/dc22-0614 · DOI
  13. Grams, 2019, Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data, J Am Soc Nephrol, 30, 1746, 10.1681/ASN.2019010008 · DOI · Paper page
  14. Neves, 2023, GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes, J Am Coll Cardiol, 82, 517, 10.1016/j.jacc.2023.05.048 · DOI

Cited by

See all 165

Metadata

Authors
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Liu, C.-C., Mahaffey, K. W., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Perkovic, V., Sabatine, M. S., Solomon, S. D., Staplin, N., Szarek, M., Vaduganathan, M., Wanner, C., Wheeler, D. C., Wiviott, S. D., Zannad, F., & Heerspink, H. J. L.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2024-08
Volume
12
Issue
8
Pages
545-557
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4400405364
Cited by
165
References
22
FWCI
15.52
Type
journal article
Language
en
Open access
green
Funders
  • National Health and Medical Research Council
  • Ramaciotti Foundations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1016/s2213-8587(24)00155-4
The paper
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Liu, C.-C., Mahaffey, K. W., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Perkovic, V., Sabatine, M. S., . . . Heerspink, H. J. L. (2024). Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00155-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.